#USA #AbbVie #North Chicago #Skyrizi #RINVOQ

AbbVie Reports First-Quarter 2025 Financial Results

AbbVie, a biopharmaceutical leader, announced its financial results for the first quarter of 2025, highlighting an impressive start to the year that exceeded expectations. For the quarter ending March 31, 2025, the company reported a net revenue of $13.343 billion, reflecting an increase of 8.4% on a reported basis or 9.8% on an operational basis.

Financial Highlights

The results brought to light several notable achievements in different therapeutic portfolios:

• - Immunology Portfolio: The net revenues reached $6.264 billion, marking a significant increase of 16.6% compared to the previous year. Noteworthy contributions came from:

- Skyrizi: $3.425 billion (up 70.5%)
- Rinvoq: $1.718 billion (up 57.2%)
- Humira: $1.121 billion (decrease of 50.6%) due to increased competition and a shifting market landscape.

• - Neuroscience Portfolio: Revenues were at $2.282 billion, an increase of 16.1%, fueled by:

- Vraylar: $765 million (up 10.3%)
- Botox Therapeutic: $866 million (up 15.8%)
- Newly introduced medications also showed promising sales trajectories.

• - Oncology Portfolio: Net revenues reached $1.633 billion, up 5.8%, demonstrating steady growth with products such as Imbruvica contributing $738 million.

• - Aesthetics Portfolio: This segment, however, saw a slight decline. Revenues of $1.102 billion represented an 11.7% drop due to shifting consumer preferences and market dynamics. Key products like Botox Cosmetic and the Juvederm collection saw decreased sales, raising concerns about competition and market saturation.

In terms of earnings, AbbVie experienced a diluted EPS of $0.72 on a GAAP basis, reflecting a decrease of 6.5%. However, the adjusted diluted EPS rose to $2.46, an increase of 6.5%. This positive adjustment reflects AbbVie's strategic moves and operational efficiencies despite adverse impacts from acquisitions and milestone expenses.

Strategic Investments and Future Outlook

CEO Robert A. Michael commented on the results, stating, "The first-quarter results were well ahead of our expectations and reflect an excellent start to the year. The fundamentals of our business are strong, and we continue to bolster our outlook with pipeline advancements and strategic investments."

Highlighting AbbVie's commitment to innovation, recent regulatory approvals and product launches bolster its growth trajectory. Notable events included the European Commission granting marketing authorization to Rinvoq for treating giant cell arteritis, expanding its application in immunology.

AbbVie has also engaged in strategic collaborations, such as its partnership with Xilio Therapeutics to develop novel immunotherapies and another with Gubra to tackle obesity with new long-acting treatments.

Full-Year 2025 Outlook

By raising its 2025 adjusted diluted EPS guidance from $11.99 - $12.19 to a slightly higher range of $12.09 - $12.29, AbbVie shows confidence in its growth trajectory. This guidance considers recent performances while excluding potential impacts from ongoing acquisitions. Company representatives emphasized that this outlook relies on stability in the trade environment, which may be subject to changes.

Conclusion

AbbVie's Q1 2025 results exhibit a promising outlook for the biopharmaceutical giant. The company's ability to drive significant revenue increases across its key therapeutic areas indicates a well-structured business model ready to adapt to future challenges. As AbbVie continues to advance its pipeline and address market dynamics, stakeholders can anticipate sustained growth and expanded market influence.